Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin versus heparin with ticagrelor during primary PCI for STEMI
ChiCTR1900022529Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of bivalirudin, ticagrelor, heparin and aspirin in myocardial infarction (MI) and coronary arteriosclerosis (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Net adverse clinical events. Started Jan 2019; status: recruiting.
02
Drugs
bivalirudinticagrelorheparinaspirin
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900022529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022529.